Compare JFU & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | TLPH |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 37.9M |
| IPO Year | 2018 | 2010 |
| Metric | JFU | TLPH |
|---|---|---|
| Price | $2.79 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 184.5K |
| Earning Date | 12-09-2022 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.38 |
| 52 Week High | $9.48 | $1.57 |
| Indicator | JFU | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 52.69 |
| Support Level | $2.43 | $0.73 |
| Resistance Level | $4.80 | $0.88 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 12.90 | 77.59 |
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.